Showing results (1-10 of 148) with videos related to
Sort By:
Pageof 15
Immunology Letters|December 9, 2004
Immune-based therapies for prostate cancerDouglas G McNeel, Miroslav MalkovskyBiomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 20, 2007
Cellular immunotherapies for prostate cancerDouglas G McNeelJournal for Immunotherapy of Cancer|November 24, 2016
TCR diversity - a universal cancer immunotherapy biomarker?Douglas G McNeelBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 30, 2017
Therapeutic Cancer Vaccines: How Much Closer Are We?Douglas G McNeelCancer Immunology, Immunotherapy : CII|June 8, 2011
Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinomaJoshua M Lang, Mahazarin R Kaikobad, Marianne Wallace, et al.Clinical Genitourinary Cancer|July 10, 2013
A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapyJoshua M Lang, Marianne Wallace, Jordan T Becker, et al.Oncoimmunology|March 28, 2022
Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expressionDonghwan Jeon, Douglas G McNeelOncoimmunology|May 19, 2023
B cells require licensing by dendritic cells to serve as primary antigen-presenting cells for plasmid DNAIchwaku Rastogi, Douglas G McNeelExpert Review of Vaccines|July 14, 2010
DNA vaccines for the treatment of prostate cancerSheeba Alam, Douglas G McNeelPageof 15